Advertisement
KYMR vs NRIX
Which Stock Would AI Choose? Kymera Therapeutics (KYMR) vs. Nurix Therapeutics (NRIX) Stock Comparison
Key Takeaways
- Both KYMR and NRIX are clinical-stage biotechs built around targeted protein degradation (TPD), a technique that tags disease-causing proteins for the body's own disposal system.
- KYMR is meaningfully larger, with a market capitalization near $9.8 billion versus roughly $2.3–2.7 billion for NRIX.
- KYMR has delivered stronger relative performance recently, up more than 50% year-to-date versus a high-teens gain for NRIX.
- Each company's lead program targets a different disease area: immunology and inflammation for KYMR, and oncology and blood cancers for NRIX.
- Both carry substantial binary, clinical-stage risk, but KYMR benefits from a deeper pipeline and larger cash balance, while NRIX leans heavily on a single Roche-backed lead asset.
Introduction
Investors scanning the biotech landscape frequently encounter companies working on the same scientific breakthrough, which makes a direct stock comparison especially useful for isolating relative strengths. KYMR and NRIX both specialize in targeted protein degradation, yet they differ sharply in scale, therapeutic focus, and market positioning. This comparison is relevant to traders and investors who want to understand how two platform-based drug developers with overlapping science diverge in momentum, pipeline breadth, and financial profile. By examining recent performance, catalysts, and risk factors side by side, readers can better assess which profile aligns with their own objectives and risk tolerance.
KYMR Overview and Recent Performance
KYMR, Kymera Therapeutics, is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. It develops oral small-molecule protein degraders, with its lead wholly owned asset, KT-621, an investigational once-daily oral STAT6 (signal transducer and activator of transcription 6) degrader being studied for type II inflammatory conditions such as atopic dermatitis and asthma.
Recent market activity has favored the stock. Shares have climbed more than 50% year-to-date, and the 52-week range extends from about $40 to roughly $130, reflecting a substantial re-rating. Sentiment has been supported by clinical execution: the company completed enrollment in its phase IIb atopic dermatitis study ahead of schedule, pulling forward expected top-line data, and received Fast Track designations from the FDA for KT-621. Financially, Kymera ended its most recent quarter with approximately $1.5 billion in cash, a runway management expects to fund operations into 2029. Collaboration revenue from partners such as Gilead and Sanofi has also contributed to top-line strength, although future revenue remains milestone-dependent. Analyst consensus is a Strong Buy with an average price target near $139.
NRIX Overview and Recent Performance
NRIX, Nurix Therapeutics, is a clinical-stage biopharmaceutical company headquartered in San Francisco, California. It focuses on protein degradation and modulation for oncology and autoimmune diseases. Its lead program, bexobrutideg (NX-5948), is an oral BTK (Bruton's tyrosine kinase) degrader being developed for B-cell malignancies, including relapsed/refractory chronic lymphocytic leukemia (CLL).
Nurix's recent performance has been shaped by a transformative partnership with Roche, which included a $700 million upfront payment and up to roughly $2.3 billion in total potential value. That deal drove a large one-time revenue spike and a brief turn to profitability in its most recent quarter, though the underlying business continues to operate at a loss on a recurring basis. The stock has gained in the high teens year-to-date and trades near $25, with a market capitalization around $2.3–2.7 billion. Analyst consensus is a Buy with an average price target near $34.50. Investor attention remains concentrated on bexobrutideg's pivotal-stage progress and the durability of its partnership economics.
Trending AI Robots
Tickeron maintains a curated selection of AI-driven trading systems on its Trending AI Robots page. The platform hosts hundreds of AI Trading Bots that collectively monitor thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Each robot operates with its own trading style, strategy, timeframe, performance record, and universe of tickers, so no two bots are alike. Because the selection is refreshed to reflect prevailing market regimes, the page serves as a useful starting point for traders who want to see which automated strategies are currently gaining traction. Explore the Trending AI Robots to review the available bots and their recent statistics.
Head-to-Head Comparison
Although both companies share a foundation in targeted protein degradation, their positioning diverges in several important ways. KYMR is a larger, better-capitalized entity with a multi-asset immunology pipeline spanning atopic dermatitis, asthma, and lupus, offering more shots on goal. NRIX is smaller and more concentrated, with its valuation and momentum tied closely to bexobrutideg and the Roche alliance.
On growth drivers, Kymera's catalysts center on multiple mid-stage readouts and an accelerated development timeline, while Nurix's story hinges on late-stage oncology data and partnership economics. Risk profiles also differ: Kymera's cash runway into 2029 reduces near-term financing risk, whereas Nurix's smaller cash base and reliance on one-time collaboration payments introduce greater funding and revenue variability. Sector exposure is another contrast—Kymera leans toward inflammatory and autoimmune diseases, while Nurix is weighted toward blood cancers. In terms of relative momentum and sentiment, Kymera has outperformed more substantially over the past year, though both carry consensus positive ratings from sell-side analysts.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, pipeline breadth, and catalyst density, Tickeron's AI would likely favor KYMR in the current environment. Its larger market capitalization, deeper cash reserves extending into 2029, multiple near-term clinical readouts, and stronger relative performance all point toward a more consistent trend and a more diversified risk profile. NRIX offers compelling upside potential tied to a single, well-funded lead asset, but its concentration and dependence on one-off partnership payments introduce greater variability. A probabilistic assessment therefore skews toward Kymera, while acknowledging that clinical data outcomes remain the decisive variable for both companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KYMR is a Buy and NRIX is a Hold.
KYMR in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for KYMR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on KYMR as a result. In 63 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for KYMR just turned positive on October 20, 2026. Looking at past instances where KYMR's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
KYMR moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where KYMR advanced for three days, in 238 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 144 of 183 cases where KYMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
KYMR broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.002) is normal, around the industry mean (3.051). P/E Ratio (-39.105) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (103.093) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. KYMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for NRIX turns negative, indicating new downward trend
NRIX saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 78 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NRIX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 21 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 51 cases where NRIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NRIX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NRIX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on October 14, 2026. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
NRIX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NRIX crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in 203 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.655) is normal, around the industry mean (3.051). P/E Ratio (-7.462) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KYMR | NRIX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 38 | 100 | |
SMR RATING 1..100 | 95 | 98 | |
PRICE GROWTH RATING 1..100 | 35 | 36 | |
P/E GROWTH RATING 1..100 | 66 | 65 | |
SEASONALITY SCORE 1..100 | 31 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KYMR's Valuation (6) in the null industry is somewhat better than the same rating for NRIX (62). This means that KYMR’s stock grew somewhat faster than NRIX’s over the last 12 months.
KYMR's Profit vs Risk Rating (38) in the null industry is somewhat better than the same rating for NRIX (100). This means that KYMR’s stock grew somewhat faster than NRIX’s over the last 12 months.
KYMR's SMR Rating (95) in the null industry is in the same range as NRIX (98). This means that KYMR’s stock grew similarly to NRIX’s over the last 12 months.
KYMR's Price Growth Rating (35) in the null industry is in the same range as NRIX (36). This means that KYMR’s stock grew similarly to NRIX’s over the last 12 months.
NRIX's P/E Growth Rating (65) in the null industry is in the same range as KYMR (66). This means that NRIX’s stock grew similarly to KYMR’s over the last 12 months.
| KYMR | NRIX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 84% |
| Advances ODDS (%) | 3 days ago 82% | 8 days ago 82% |
| Declines ODDS (%) | 13 days ago 86% | 3 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 78% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KYMR’s FA Score shows that 1 FA rating(s) are green while NRIX’s FA Score has 0 green FA rating(s).
- KYMR’s FA Score: 1 green, 4 red.
- NRIX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KYMR’s TA Score shows that 6 TA indicator(s) are bullish while NRIX’s TA Score has 4 bullish TA indicator(s).
- KYMR’s TA Score: 6 bullish, 4 bearish.
- NRIX’s TA Score: 4 bullish, 6 bearish.
Price Growth
KYMR (@Biotechnology) experienced а +8.10% price change this week, while NRIX (@Biotechnology) price change was -3.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.61%. For the same industry, the average monthly price growth was -11.21%, and the average quarterly price growth was -16.43%.
Reported Earning Dates
KYMR is expected to report earnings on Feb 25, 2027.
NRIX is expected to report earnings on Feb 17, 2027.
Industries' Descriptions
@Biotechnology (-3.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KYMR and
Correlation & Price change
A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with GPCR. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then GPCR could also see price increases.
| Ticker / NAME | Correlation To KYMR | 1D Price Change % | ||
|---|---|---|---|---|
| KYMR | 100% | -0.33% | ||
| GPCR - KYMR | 63% Loosely correlated | -0.59% | ||
| NRIX - KYMR | 58% Loosely correlated | +0.47% | ||
| WVE - KYMR | 52% Loosely correlated | +1.70% | ||
| CGEM - KYMR | 44% Loosely correlated | +5.49% | ||
| REPL - KYMR | 44% Loosely correlated | +5.95% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QPUX | 5.63 | 0.33 | +6.23% |
| Defiance 2X Daily Long Pure Quantum ETF (QPUX) | |||
| KF | 55.39 | 1.13 | +2.08% |
| Korea Fund | |||
| CATH | 89.74 | 0.28 | +0.32% |
| Global X S&P 500 Catholic Values Custom ETF (CATH) | |||
| SEPP | 33.00 | 0.07 | +0.22% |
| PGIM S&P 500 Buffer 12 ETF - September (SEPP) | |||
| CWY | 12.64 | 0.01 | +0.11% |
| GraniteShares YieldBOOST CRWV ETF (CWY) | |||